Malignant Pleural Effusion Market Report 2026

Malignant Pleural Effusion Market Overview

• Malignant Pleural Effusion market size has reached to $4.73 billion in 2025 • Expected to grow to $6.52 billion in 2030 at a compound annual growth rate (CAGR) of 6.6% • Growth Driver: Rising Cases Of Lung Cancer Driving The Growth Of The Market Due To Increasing Treatment Demand • Market Trend: Advanced, Minimally Invasive Solutions To Improve Outcomes In Malignant Pleural Effusion Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Malignant Pleural Effusion Market?

Malignant pleural effusion (MPE) refers to the accumulation of fluid in the pleural space due to the presence of cancer cells, typically resulting from metastatic disease. This condition occurs when cancer spreads to the pleura, the thin membrane surrounding the lungs, leading to increased vascular permeability and impaired lymphatic drainage. The main treatment types for malignant pleural effusion include systemic therapy, therapeutic thoracentesis, thoracic drainage and pleurodesis, and indwelling pleural catheter placement. Systemic therapy is a cancer treatment that circulates through the bloodstream to target and eliminate cancer cells throughout the body. This is diagnosed using various methods, such as pleural fluid cytology, immunohistochemical tests, imaging tests, pleural thoracentesis, pleuroscopy, and pleural biopsy. These treatments and diagnostic methods are utilized by various end users, including hospitals, ambulatory clinics, and other healthcare facilities.

What Is The Malignant Pleural Effusion Market Growth Forecast?

The malignant pleural effusion market size is expected to see strong growth in the next few years. It will grow to $6.52 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to rising cancer prevalence worldwide, advancements in pleural catheter technologies, increasing emphasis on outpatient and home-based care, improved diagnostic imaging accuracy, growing demand for quality-of-life–focused treatments. Major trends in the forecast period include increasing use of indwelling pleural catheters for long-term management, rising preference for minimally invasive pleural interventions, growing integration of systemic cancer therapies in mpe management, higher focus on symptom relief and palliative care approaches, expansion of imaging-guided diagnostic and therapeutic procedures.

Global Malignant Pleural Effusion Market Segmentation

1) By Treatment: Systemic Therapy, Therapeutic Thoracentesis, Thoracic Drainage And Pleurodesis, Indwelling Pleural Catheter 2) By Diagnosis: Pleural Fluid Cytology, Immunohistochemical Tests, Imaging Tests, Pleural Thoracentosis, Pleuroscopy, Pleural Biopsy 3) By End Users: Hospitals, Ambulatory Clinics, Other End Users Subsegments: 1) By Systemic Therapy: Chemotherapy, Targeted Therapy, Immunotherapy 2) By Therapeutic Thoracentesis: Single-Time Thoracentesis, Repeated Thoracentesis 3) By Thoracic Drainage And Pleurodesis: Chemical Pleurodesis, Mechanical Pleurodesis 4) By Indwelling Pleural Catheter: Tunneled Pleural Catheter, Non-Tunneled Pleural Catheter

What Are The Drivers Of The Malignant Pleural Effusion Market?

The rising cases of lung cancer is expected to propel the growth of the malignant pleural effusion market going forward. Lung cancer is a disease characterized by the uncontrolled growth of abnormal cells in the lungs, which can form tumors and interfere with normal lung function. The rising cases of lung cancer are due to smoking and tobacco use, as prolonged exposure to harmful chemicals in cigarettes damages lung tissues, triggers genetic mutations, and promotes the uncontrolled growth of cancerous cells, significantly increasing the likelihood of developing the disease. Malignant pleural effusion indicates advanced lung cancer progression by facilitating tumor spread within the pleural cavity, leading to worsened respiratory function and a poorer prognosis. For instance, in January 2023, according to the American Cancer Society Facts and Figures, a US-based professional organizations company, the estimated number of new lung and bronchus cancer cases was 236,740 in 2022 and 238,340 in 2023, while the estimated deaths were 130,180 in 2022 and 127,070 in 2023. Therefore, the rising cases of lung cancer is driving the growth of the malignant pleural effusion industry. The improving healthcare infrastructure is expected to propel the growth of the malignant pleural effusion market going forward. Healthcare infrastructure refers to the physical, technological, and organizational structures required for delivering healthcare services, including hospitals, clinics, medical equipment, IT systems, and workforce. Improving healthcare infrastructure is attributed to need for better disease management, all of which contribute to enhanced healthcare accessibility, efficiency, and quality of care. Improving healthcare infrastructure enhances the diagnosis, treatment, and management of malignant pleural effusion by enabling access to advanced medical technologies, better-equipped healthcare facilities, and specialized care, ultimately improving patient outcomes. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the number of hospitals in the United States increased by 0.591% from the previous year, rising from 6,093 to 6,129. Therefore, the improving healthcare infrastructure is driving the growth of the malignant pleural effusion industry.

Key Players In The Global Malignant Pleural Effusion Market

Major companies operating in the malignant pleural effusion market are Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc, Argon Medical Devices Inc, B Braun SE, Medtronic plc, Smiths Medical, Teleflex Incorporated, Cardinal Health Inc, Getinge AB, AngioDynamics Inc, Rocket Medical plc, Redax SpA, Atrium Medical Corporation, PolyMedicure Ltd, Troge Medical GmbH, Vygon SA, ICU Medical Inc, ConvaTec Group plc, Baxter International Inc

Global Malignant Pleural Effusion Market Trends and Insights

Major companies operating in the malignant pleural effusion market are focusing on developing innovative products such as fully-implantable automatic fluid-shunt devices to improve patient comfort and reduce hospital visits. A fully-implantable automatic fluid-shunt device is a medical device implanted in the body that automatically drains excess pleural fluid from the lungs into the abdomen or another area, helping to relieve symptoms of breathlessness, reduce the need for repeated hospital procedures, and improve patient quality of life. For instance, in October 2023, Pleural Dynamics, a US-based medical device company, launched the ACES Automatic Continuous Effusion Shunt System. This device comprises a resilient flexible pump chamber implanted under the skin between the ribs, with one catheter in the pleural space and another in the peritoneal space. As the patient breathes, the internal pump extension is compressed and decompressed between adjacent ribs, driving fluid from the pleural cavity to the abdomen where it is reabsorbed; the system also allows manual activation via an external compression extension. Key features include: fully implantable design, no external drainage tubing or suction bottles, breathing-powered automatic pumping function, minimal hospital stay for implantation, and continuous symptom relief from recurrent effusions.

Regional Outlook

North America was the largest region in the malignant pleural effusion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Malignant Pleural Effusion Market?

The malignant pleural effusion market consists of revenues earned by entities by providing services such as biopsy and cytology testing, chemotherapy and targeted therapy, and pleurodesis. The market value includes the value of related goods sold by the service provider or included within the service offering. The malignant pleural effusion market also includes sales of chest drainage systems, pleural access kits, and imaging-guided drainage equipment, and thoracentesis devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Malignant Pleural Effusion Market Report 2026?

The malignant pleural effusion market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the malignant pleural effusion industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.